$-0.06 EPS Expected for NovaBay Pharmaceuticals, Inc. (NBY); Intellisync (SYNC) Sentiment Is 1.13

April 17, 2018 - By mmahotstuff

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Logo

Analysts expect NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) to report $-0.06 EPS on May, 10.They anticipate $0.20 EPS change or 76.92% from last quarter’s $-0.26 EPS. After having $0.02 EPS previously, NovaBay Pharmaceuticals, Inc.’s analysts see -400.00% EPS growth. The stock increased 1.59% or $0.05 during the last trading session, reaching $3.2. About 399 shares traded. NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has declined 12.00% since April 17, 2017 and is downtrending. It has underperformed by 23.55% the S&P500.

Intellisync Corp (SYNC) investors sentiment increased to 1.13 in 2017 Q4. It’s up 0.07, from 1.06 in 2017Q3. The ratio is better, as 18 active investment managers started new or increased stock positions, while 16 decreased and sold their stock positions in Intellisync Corp. The active investment managers in our database now hold: 11.76 million shares, up from 11.61 million shares in 2017Q3. Also, the number of active investment managers holding Intellisync Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 12 Increased: 11 New Position: 7.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $54.69 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

Northpointe Capital Llc holds 0.42% of its portfolio in Synacor, Inc. for 1.63 million shares. Raffles Associates Lp owns 80,539 shares or 0.19% of their US portfolio. Moreover, Ariel Investments Llc has 0.1% invested in the company for 3.78 million shares. The Us-based Ancora Advisors Llc has invested 0.05% in the stock. Alyeska Investment Group L.P., a Illinois-based fund reported 1.02 million shares.

Ratings analysis reveals 100% of Synacor’s analysts are positive. Out of 2 Wall Street analysts rating Synacor, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5.5 while the high is $7.0. The stock’s average target of $6.25 is 303.23% above today’s ($1.55) share price. SYNC was included in 2 notes of analysts from October 18, 2016. The rating was initiated by Lake Street on Tuesday, February 14 with “Buy”. The stock has “Buy” rating by Ladenburg Thalmann on Tuesday, October 18.

The stock increased 3.33% or $0.05 during the last trading session, reaching $1.55. About 31,526 shares traded. Synacor, Inc. (SYNC) has declined 58.97% since April 17, 2017 and is downtrending. It has underperformed by 70.52% the S&P500.

Synacor, Inc. operates as a technology development, multiplatform services, and revenue partner for video, Internet, and communications providers; and device manufacturers, governments, and enterprises. The company has market cap of $60.14 million. It enables its clients to provide their clients engaging, multiscreen experiences with products that require scale, and actionable data and implementation. It currently has negative earnings. The company, through its managed portals and advertising solutions, enables its clients to earn revenue by monetizing media among their consumers.

Synacor, Inc. (NASDAQ:SYNC) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>